このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Eating Disorders in Patients With IBD

2026年5月27日 更新者:Fabiana Castiglione、Federico II University

Prevalence of Eating Disorders in Patients With Inflammatory Bowel Disease

Inflammatory bowel diseases (IBD) may influence eating habits and lead some patients to adopt restrictive dietary behaviours to control gastrointestinal symptoms. In some cases, these behaviours may become maladaptive and resemble eating disorders, including avoidant/restrictive food intake disorder (ARFID).

This observational cross-sectional study assesses the prevalence of eating disorder risk and ARFID risk among adult patients with IBD. Participants complete validated questionnaires evaluating eating behaviours, nutritional status, and IBD-related disability. Clinical and demographic data are also collected.

調査の概要

詳細な説明

Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic relapsing conditions characterized by persistent inflammatory activity, unpredictable disease course, and recurrent gastrointestinal symptoms. These factors may substantially influence patients' dietary habits. Many patients with IBD modify or restrict their diet in an attempt to prevent symptom exacerbation or disease flares. Although dietary restriction may represent an adaptive behaviour during active disease, it may persist over time and become maladaptive.

Restrictive eating behaviours in IBD may overlap with eating disorders, including avoidant/restrictive food intake disorder (ARFID). ARFID is characterized by restrictive food intake that is not primarily driven by body image concerns, but rather by mechanisms such as fear of adverse gastrointestinal consequences, low appetite or reduced interest in eating, and avoidance of specific foods. In patients with IBD, these behaviours may contribute to nutritional impairment, psychological distress, and disability.

This observational cross-sectional study assesses the prevalence of eating disorder risk and ARFID risk among adult patients with a confirmed diagnosis of IBD. Consecutive eligible patients are enrolled during routine outpatient visits. Demographic and clinical data are collected at enrolment, including disease type, age at diagnosis, disease duration, disease phenotype, previous treatments, previous surgery, extraintestinal manifestations, current therapy, laboratory markers, and disease activity.

Eating disorder risk is assessed using the Eating Attitudes Test-26 (EAT-26). ARFID risk is evaluated using the Nine-Item Avoidant/Restrictive Food Intake Disorder Screen (NIAS-9), including its subdomains related to picky eating, low appetite or limited interest in eating, and fear of adverse consequences. Nutritional status is assessed using the Patient-Generated Subjective Global Assessment (PG-SGA). IBD-related disability is evaluated using the IBD-Disk and a modified IBD-Disk including a diet-related item.

Clinical disease activity is assessed using validated disease-specific indices, including the partial Mayo score for ulcerative colitis and the Harvey-Bradshaw Index for Crohn's disease. Endoscopic activity, when available, is evaluated using the Mayo Endoscopic Subscore for ulcerative colitis and the Simple Endoscopic Score for Crohn's Disease for Crohn's disease. The study also evaluates associations between altered eating behaviours, disease activity, malnutrition risk, dietary impairment, and IBD-related disability.

The study aims to improve the identification of patients with IBD who are at risk of maladaptive restrictive eating behaviours and who may benefit from structured nutritional or psychological assessment as part of routine IBD care. The uploaded study describes the same core design elements: adult IBD patients enrolled during routine outpatient visits, ARFID risk assessed with NIAS-9, eating disorder risk with EAT-26, nutritional status with PG-SGA, and disability with IBD-Disk/mDISK. 

研究の種類

観察的

入学 (実際)

355

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Naples、イタリア、80131
        • University of Naples Federico II

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

サンプリング方法

確率サンプル

調査対象母集団

Adult patients with a confirmed diagnosis of inflammatory bowel disease, including Crohn's disease or ulcerative colitis, enrolled during routine outpatient visits at participating IBD centres. Participants complete validated questionnaires assessing eating behaviours, nutritional status, and IBD-related disability, with concurrent collection of clinical and demographic data.

説明

Inclusion Criteria:

  • Adult patients aged 18 years or older.
  • Confirmed diagnosis of inflammatory bowel disease, including Crohn's disease or ulcerative colitis.
  • Patients evaluated during routine outpatient IBD visits.
  • Ability to understand and complete the study questionnaires.

Exclusion Criteria:

  • Previous diagnosis or known history of eating disorders.
  • Severe unmanaged psychiatric conditions.
  • Pregnancy.
  • Inability to complete the questionnaires or provide reliable study information.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
Adult patients diagnosed with Inflammatory Bowel Disease
Adult patients with a confirmed diagnosis of inflammatory bowel disease, including Crohn's disease or ulcerative colitis, enrolled during routine outpatient visits.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Prevalence of avoidant/restrictive food intake disorder risk among adult patients with inflammatory bowel disease
時間枠:Single time point at enrolment
The primary outcome is the proportion of adult patients with inflammatory bowel disease who screen positive for avoidant/restrictive food intake disorder risk. ARFID risk is assessed using the validated Nine-Item Avoidant/Restrictive Food Intake Disorder Screen (NIAS-9), which evaluates restrictive eating behaviours across three domains: picky eating, low appetite or limited interest in eating, and fear of adverse consequences. A NIAS-9 total score of 24 or higher identifies participants at risk for ARFID.
Single time point at enrolment

二次結果の測定

結果測定
メジャーの説明
時間枠
Prevalence of eating disorder risk among adult patients with inflammatory bowel disease
時間枠:Single time point at enrolment
The proportion of adult patients with inflammatory bowel disease who screen positive for eating disorder risk. Eating disorder risk is assessed using the validated Eating Attitudes Test-26 (EAT-26). A total EAT-26 score of 20 or higher identifies participants at risk for eating disorders and indicates the need for further clinical evaluation.
Single time point at enrolment
Association between ARFID risk and malnutrition risk
時間枠:Single time point at enrolment
The association between avoidant/restrictive food intake disorder risk and malnutrition risk among adult patients with inflammatory bowel disease. ARFID risk is assessed using the Nine-Item Avoidant/Restrictive Food Intake Disorder Screen (NIAS-9), while nutritional status is evaluated using the Patient-Generated Subjective Global Assessment (PG-SGA). A PG-SGA (ranging 0-36) score of 6 or higher identifies participants at high risk of malnutrition.
Single time point at enrolment
Association between avoidant/restrictive food intake disorder risk and IBD-related disability
時間枠:Single time point at enrolment
This outcome assesses the association between avoidant/restrictive food intake disorder risk and inflammatory bowel disease-related disability. ARFID risk is assessed using the Nine-Item Avoidant/Restrictive Food Intake Disorder Screen (NIAS-9). IBD-related disability is assessed using the IBD-Disk (score ranging 0-100), a patient-reported instrument evaluating the impact of IBD on symptoms, daily functioning, and psychosocial well-being. Moderate-to-severe disability is defined as an IBD-Disk score of 40 or higher.
Single time point at enrolment

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年10月10日

一次修了 (実際)

2025年4月1日

研究の完了 (実際)

2025年4月1日

試験登録日

最初に提出

2026年5月19日

QC基準を満たした最初の提出物

2026年5月27日

最初の投稿 (実際)

2026年5月28日

学習記録の更新

投稿された最後の更新 (実際)

2026年5月28日

QC基準を満たした最後の更新が送信されました

2026年5月27日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data will not be shared because the dataset includes sensitive clinical and questionnaire-based information. Aggregate results will be shared through publications and scientific presentations.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する